Star Trek, the classic sci-fi TV series, depicted a far-off future where space explorers traveled the galaxies equipped with cutting edge technology such as a communicator, food replicator and the indispensable tricorder, a hand-held medical device that could scan a person’s vital signs, issue a diagnosis and prescribe treatment in minutes.
Equity portfolio manager Rich Wolf expects that within the next 10 years such devices will be a reality. “For years I’ve been around bioengineers who have joked about having a tricorder,” says Wolf, who also covers U.S. medical technology companies as an investment analyst. “While I don’t think there is going to be a single tricorder that does everything, I suspect that by 2030 many of us will have devices like it that will analyze blood, do cardiology monitoring and even remotely check our breathing while we sleep.”
We are in the midst of a massive wave of innovation and disruption across the health care sector that has the potential to drive new opportunity for companies, reduce overall medical costs and, most importantly, improve outcomes for patients.“ There’s never been a more exciting time in health care, says Wolf. “The last time we were close was about 20 years ago when the human genome was first sequenced. That was an important first step. Today we are seeing major advances that have resulted from that first step.”
The COVID-19 pandemic and race to develop a vaccine highlights the important role drugs can play in improving people’s health and longevity, but the wave of innovation reaches far beyond the pharmaceutical and biotech industries. Not only are we hearing news of new drug therapies seemingly every day, but leaps in research tools, diagnostics and remote patient monitoring are converging to change the face of health care.
Wolf and equity portfolio manager Cheryl Frank recently sat down to share their perspective on the health care trends they expect will transform the investing landscape over the next 10 years.
When the human genome was first sequenced about two decades ago, it took a team of researchers nearly eight years at a cost of more than US$100 million. Today, a human genome can be sequenced in a matter of days for about US$1,000. Subsequent breakthroughs in DNA analysis have led to a new era in the medicine. ”Today we can compare the map of the human genome to mutations that exist as a function of cancer,” Wolf says. “We can then identify specific mutations in the cancer and match therapies to them. We can do a much better job of treating patients as a function of understanding that code.”
Indeed, genomics research and therapies derived from genetic testing have the potential to extend lives and generate billions of dollars in revenue for the companies that develop them. U.S. drugmaker Merck, the maker of blockbuster immunotherapy treatment Keytruda, biopharma companies like Gilead Sciences and others have invested millions of dollars to develop gene-based treatments for various cancers, including bladder cancer and melanoma.
Vastly reduced costs and scientific developments have contributed to phenomenal growth in medical science research and development (R&D). “We're in a renaissance period for R&D, and companies are investing aggressively to find unique ways to battle cancer and other illnesses,” Frank says. “We're seeing unprecedented rates in terms of progression-free survival for many types of cancer.”
Drugmakers are not the only companies that can potentially benefit from these advances. A broad range of companies like genetic testing equipment maker Illumina and research and manufacturing company Thermo Fisher Scientific are providing services to a host of drug developers.
Broader advances in technology, like greater connectivity and artificial intelligence, are helping to turbocharge the development of therapies, says Frank. “I think many types of cancer will be effectively cured by 2030,” she says. “We're already using sophisticated tools that predict the behaviour of molecules and reduce the need to create as many molecules. And I think we'll use data more effectively in the future to identify which patients will most benefit from developed therapies.”
The U.S. remains a world leader in innovation for a number of reasons, but clearly America will not be the only source of pharmaceutical innovation going forward, says Frank, who has covered the health care industry for 18 years.
“I expect to see many global blockbuster drugs from China by 2030. I anticipate they will begin to produce novel drugs for cancer within five to 10 years and sell them at one-tenth the cost in the U.S.,” she says.
Breakthroughs in diagnostics are helping to lead to earlier detection of illnesses, which can help make drugs more effective — or in some cases prevent disease before it ever happens. “One of the most exciting things in health care today is something known as liquid biopsy, whereby a sample of your blood can be used to identify a tumor at the very earliest stages,” notes Wolf.
A patient could visit their physician for a yearly checkup, have blood work done and find out whether they have any cancer. “Early detection is key to curing cancer,” he adds.
But ongoing innovation in diagnostics isn’t confined to the hospital or doctor’s office. Home diagnostics — including continuous glucose monitors, insulin pumps, implantable EKG loop recorders and connected sleep apnea devices — are increasingly enabling physicians to monitor patients remotely.
A broad range of traditional tech and medtech companies have been working to develop home diagnostics for some time. “In the last five years we've seen a big move among great tech minds combining their expertise with great health care minds, and this is very important,” Wolf says. We are still in the early stages of the development of cost-efficient devices that can collect all kinds of health-related metrics that can not only help coach us to improve our own health, but can also be sent immediately to your doctor.”
Telemedicine, or patient-doctor consultations online rather than in person, has been available for some time, but until early this year its adoption rate had been quite low, but that changed when the COVID-19 pandemic struck. What’s more, regulators and health care providers relaxed their rules to allow more digitalization.
Today, many consumers have had their first telehealth experience. Frank believes this is a trend that is likely to endure. “I believe the combination of telehealth, at-home diagnostics and medicine delivery will enable almost everything to become treatable from home,” Frank says. “Personal devices will use this data to help us improve our health.”
As an example, Frank cites a colleague who became pregnant during the pandemic. She ordered a Doppler machine, measuring tape and a blood pressure cuff on the internet and had several prenatal appointments online.
Perhaps the biggest change will be patients taking greater control of their health care thanks to the combination of technologies, Wolf says. Health care costs have been soaring for years and are projected to rise. But the rise in telehealth and vast improvements in the quality of information available to patients could drive a shift in the nature of care.
“We are near a tipping point in health care expenses as a function of GDP, but I think something has changed in a big way for not only the delivery of care but the bending of the cost curve,” Wolf says.
Price discovery in the health care field has been poor. “If you ask the average person what they paid for their TV or car, they can tell you within a few dollars, but not so with their recent medical treatments,” Wolf says. Today, a company like GoodRx can notify a patient if a drug is cheaper across town than at the local drugstore [in the U.S.]. “The fact that patients are becoming much more engaged in health care is driving an incredible paradigm shift in the way health care is consumed and delivered.”
To be sure, not all innovators turn out to be great investments. The good news/bad news is that innovators come in all shapes and sizes. Both small, nimble companies and health care giants have the potential to be winners in the next generation of health care delivery. But there will also be some spectacular failures among companies both small and large. While innovation is a key element for the success of companies in such a dynamic field, strong management and strong capital allocation are also important.
Identifying the winners of the next decade will require deep research and the ability to look beyond the near term. “At Capital Group, we have the luxury of focusing on the long term,” Wolf says. “Much of the focus today is on the pandemic and vaccine development. These are very important, but we are also looking over the horizon, trying to determine how health care will be transformed over the next decade and how we can invest in those shifts.”
Our latest insights
Technology & Innovation
Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.
Unless otherwise indicated, the investment professionals featured do not manage Capital Group‘s Canadian mutual funds.
References to particular companies or securities, if any, are included for informational or illustrative purposes only and should not be considered as an endorsement by Capital Group. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds or current holdings of any investment funds. These views should not be considered as investment advice nor should they be considered a recommendation to buy or sell.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and not be comprehensive or to provide advice. For informational purposes only; not intended to provide tax, legal or financial advice. We assume no liability for any inaccurate, delayed or incomplete information, nor for any actions taken in reliance thereon. The information contained herein has been supplied without verification by us and may be subject to change. Capital Group funds are available in Canada through registered dealers. For more information, please consult your financial and tax advisors for your individual situation.
Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made herein. We encourage you to consider these and other factors carefully before making any investment decisions and we urge you to avoid placing undue reliance on forward-looking statements.
The S&P 500 Composite Index (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Capital Group. Copyright © 2023 S&P Dow Jones Indices LLC, a division of S&P Global, and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC.
FTSE source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2023. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under licence. All rights in the FTSE Russell indices or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indices or data and no party may rely on any indices or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. The index is unmanaged and cannot be invested in directly.
BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.
MSCI does not approve, review or produce reports published on this site, makes no express or implied warranties or representations and is not liable whatsoever for any data represented. You may not redistribute MSCI data or use it as a basis for other indices or investment products.
Capital believes the software and information from FactSet to be reliable. However, Capital cannot be responsible for inaccuracies, incomplete information or updating of the information furnished by FactSet. The information provided in this report is meant to give you an approximate account of the fund/manager's characteristics for the specified date. This information is not indicative of future Capital investment decisions and is not used as part of our investment decision-making process.
Indices are unmanaged and cannot be invested in directly. Returns represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
All Capital Group trademarks are owned by The Capital Group Companies, Inc. or an affiliated company in Canada, the U.S. and other countries. All other company names mentioned are the property of their respective companies.
Capital Group funds are offered in Canada by Capital International Asset Management (Canada), Inc., part of Capital Group, a global investment management firm originating in Los Angeles, California in 1931. Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.
The Capital Group funds offered on this website are available only to Canadian residents.